Lonza's new manufacturing lines will be dedicated to the production of antibody-drug conjugates (or ADCs), biopharmaceuticals that deliver targeted therapy for the treatment of cancer.
As part of its Ibex facilities, no less than 1,500 square meters of surface area will be developed in a pre-existing "shell" in Visp, in the canton of Valais. The new ADC manufacturing facilities will be supplemented by quality control laboratories, logistics infrastructure and other central services. According to Lonza, this will accelerate the speed to market, guarantee deliveries and achieve high performance.
Two different cancer therapies will be produced on site. This new specialized facility will employ approximately 200 people and is expected to be operational by the end of 2022.
Innovative treatment possibilities
ADCs are bioconjugates and represent an innovative and rapidly developing therapeutic modality that provides effective therapies for patients with reduced side effects. ADCs typically combine an antibody with a very potent payload (through a binding molecule) to better target cancer cells.
Lonza has developed the specific expertise and technology to address the risks associated with the development and manufacture of bioconjugates and now supports the majority of commercially approved ADCs. In addition, Lonza also offers all components of a complex supply chain, including the manufacturing of biomolecules, synthetic molecular fillers, connectors and their subsequent conjugation in one location.